Pharmacy Technician Pulse

Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment (January 2024)

PharmExec

JANUARY 16, 2024

Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies.

Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment

PharmExec

JANUARY 17, 2024

Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies.

The Business Case for Patient Centricity

PharmExec

AUGUST 1, 2023

Sharon Suchotliff, associate principal at ZS and lead for patient centricity, discusses why patient centricity has become a business imperative for life sciences companies.

Deep Dive: Patients and Partnerships 2022

pharmaphorum

OCTOBER 27, 2022

However, fostering lasting and meaningful partnerships is not a simple task for life science companies. Patient centricity initiatives often suffer when leadership changes and the patient-centric culture isn’t codified in KPIs, says Sharon Suchotliff, associate principal at ZS Associates. Company profile: ZS Associates.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

Patient centricity is becoming business critical for pharma

pharmaphorum

SEPTEMBER 21, 2022

That’s according to Sharon Suchotliff, patient centricity lead at consultancy firm ZS Associates, which has just published a book on the art of patient involvement. In 2019, ZS Associates carried out a global survey of pharmaceutical companies to get a better idea of patient centricity perceptions and behaviours.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

Why real patient centricity is more essential than ever before

pharmaphorum

NOVEMBER 8, 2022

Ask nearly any pharma company these days if they’re patient-centric, and you’ll probably get an answer in the affirmative. Suchotliff sat down with Deep Dive to discuss the current state of patient centricity in pharma, some of the common foibles and misconceptions, and how pharma companies can get themselves on the right track.

Highlights From Reuter’s Pharma USA 2022 | Philadelphia Convention Center

Pharma Marketing Network

MARCH 20, 2022

Kumar Ritwik of ZS Pharma showcased the importance of AI and using modular content to truly customize and personalize information to the point where “less is more” in terms of engaging with your HCPs in ways they respond to.

FDA

NICE expands cover for AZ’s high potassium drug Lokelma

pharmaphorum

JANUARY 24, 2022

AZ added Lokelma to its pipeline after buying ZS Pharma, the US company that developed it, for $2.7 NICE says that Lokelma can be used for non-dialysed patients with CKD or heart failure who have persistent hyperkalaemia with a potassium level of 6.0 mmol/litre or more that is preventing them from recommended treatment with RAAS drugs.

Hospitals

Hospitals FDA

Getting Creative with Sustainability | How Pharma Engages

Pharma Marketing Network

DECEMBER 17, 2021

The wave of interest in sustainability follows the value chain from top-tier pharmaceutical companies to their suppliers of every size. About 80% of pharmaceutical companies have announced a commitment to becoming carbon-neutral or made a net-zero pledge for carbon emissions. Where do most organizations start?

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Communication

A history of AstraZeneca

pharmaphorum

SEPTEMBER 18, 2020

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company’s story, from its creation as a merger of two equals, to its recent major restructuring and its drives in cutting-edge oncology and COVID-19. Responding to these pressures, Astra began to look for partners.

Vaccines

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA

Experts discuss the field force’s customer-centric future

pharmaphorum

JUNE 7, 2021

There are also more companies investing in technology and infrastructure to enable data-driven decision making. “A But the study also showed that many companies were hesitating or were unable to roll out these activities. Beyond data-driven segmentation, companies will also need new metrics to assess the outcomes of these approaches.

Communication

The 7 Most Common Nutrient Deficiencies in Hashimoto’s

The Thyroid Pharmacist

OCTOBER 1, 2022

This company allows patients to order their own labs (and receive the results), but also allows them to submit their receipts to their insurance for billing! Please be sure to check with your insurance, as each company has different rules. Markomanolaki ZS, Tigani X, Siamatras T, et al. Action Steps. 2019;127(7):417-422.

Adverse Reactions

Adverse Reactions Dosage Insurance Immunization

Pharmacy Technician Pulse

Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment (January 2024)

Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment

Trending Sources

The Business Case for Patient Centricity

Deep Dive: Patients and Partnerships 2022

Patient centricity is becoming business critical for pharma

Why real patient centricity is more essential than ever before

Highlights From Reuter’s Pharma USA 2022 | Philadelphia Convention Center

NICE expands cover for AZ’s high potassium drug Lokelma

Getting Creative with Sustainability | How Pharma Engages

A history of AstraZeneca

Experts discuss the field force’s customer-centric future

The 7 Most Common Nutrient Deficiencies in Hashimoto’s

Stay Connected